Minimal residual disease (MRD) monitoring in chronic myelogenous leukemia (CML) patients treated with STI571 (Glivec®)

被引：0
|
作者：
Roche-Lestienne, C
Grardel-Duflos, N
Cornu-Soenen, V
Laï, JL
Roumier, C
Berthaud, P
Cosson, A
Facon, T
Preudhomme, C
机构：
来源：
LEUKEMIA | 2001年 / 15卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2023 / 2023
页数：1
相关论文
共 50 条
  • [21] Monitoring the response of CML patients treated with STI571 by molecular cytogenetics and quantitative RT-PCR.
    Paschka, P
    Schoch, C
    Lahaye, T
    Weisser, A
    Kuhn, C
    La Rosée, P
    Kreil, S
    Berger, U
    Haferlach, T
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    BLOOD, 2000, 96 (11) : 734A - 734A
  • [22] The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia
    Sato, N
    Narita, M
    Takahashi, M
    Yagisawa, K
    Liu, A
    Abe, T
    Nikkuni, K
    Furukawa, T
    Toba, K
    Aizawa, Y
    HEMATOLOGICAL ONCOLOGY, 2003, 21 (02) : 67 - 75
  • [23] Value of interphase fluorescent in situ hybridization (iFISH) studies in monitoring response to STI571 therapy in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    Kantarjian, HM
    O'Brien, S
    Hayes, KJ
    Glassman, AB
    Faderl, S
    Thomas, D
    Rios, MB
    Capdeville, R
    Talpaz, M
    BLOOD, 2000, 96 (11) : 255B - 255B
  • [24] Minimal residual disease (MRD) analysis of BCR-ABL positive acute lymphocytic leukemia (ALL) patients during STI571 kinase inhibitor therapy.
    Scheuring, UJ
    Wassmann, B
    Pfeiffer, H
    Capdeville, R
    Petershofen, E
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2000, 96 (11) : 465A - 465A
  • [25] Impact of interferon-αtherapy duration and chronic myelogenous leukemia (CML) history on Glivec ® (STI 571) response in interferon-resistant or intolerant CML patients in chronic and in accelerated phase.
    Michallet, M
    Le, QH
    Mates, M
    Berthaud, P
    Troncy, J
    Fiere, D
    Nicolini, F
    BLOOD, 2001, 98 (11) : 263B - 263B
  • [26] Real-time quantitative RT-PCR monitoring of tyrosine kinase inhibitor (STI571/imatinib) treated chronic myelogenous leukemia patients.
    Bories, D
    Chami, I
    Perot, C
    Vandenakker, J
    Yacouben, K
    Geraudier, S
    Pautas, C
    Kuentz, M
    Cordonnier, C
    Berthaud, P
    Tulliez, M
    BLOOD, 2001, 98 (11) : 615A - 616A
  • [27] Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571
    Wolff, NC
    Ilaria, RL
    BLOOD, 2001, 98 (09) : 2808 - 2816
  • [28] Comparison of the action of NSC 680410 and STI571 in chronic myelogenous leukemia cells in vitro.
    Mow, BM
    Hallgren, CG
    Svingen, PA
    Tefferi, A
    Sausville, EA
    Kaufmann, SH
    BLOOD, 2000, 96 (11) : 346A - 346A
  • [29] Minimal residual disease (MRD) after hyper-CVAD and imatinib mesylate (STI571) for Philadelphia (Ph) positive adult acute lymphoblastic leukemia (ALL).
    Thomas, DA
    Cortes, J
    Garcia-Manero, G
    Faderl, S
    O'Brien, S
    Pierce, S
    Verstovsek, S
    Giles, FJ
    Andreeff, M
    Kornblau, SM
    Letvak, L
    Kantarjian, HM
    BLOOD, 2002, 100 (11) : 764A - 764A
  • [30] Prognostic relevance of minimal residual disease (MRD) analysis in BCR-ABL positive acute lymphoblastic leukemia (ALL) patients during Gleevec (STI571) therapy.
    Scheuring, UJ
    Pfeifer, H
    Brueck, P
    Wassmann, B
    Atta, J
    Gschaidmeier, H
    Petershofen, E
    Hoelzer, DF
    Ottmann, OG
    BLOOD, 2001, 98 (11) : 762A - 763A
12345